Sergey Axenovich

Sergey Axenovich joined Biomark Capital in November 2013. Before joining Biomark Capital, Dr. Axenovich was a Director at Burrill & Company where he was responsible for sourcing, evaluating, and executing investment transactions. Previously, Sergey managed the cancer drug discovery program and associated corporate collaborations at PPD. He began his research career at Genome Therapeutics. Subsequently, he received his MBA from the University of California, Berkeley Haas School of Business. Sergey has a Ph.D. in Molecular Genetics from the University of Illinois, Chicago, and an undergraduate degree in Molecular Biology from Moscow University.